Minerva Neurosciences (NERV) Stock Price, News & Analysis

Company Overview

Minerva Neurosciences, Inc. is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder. Roluperidone is designed to modulate a combination of sigma and adrenergic receptors without dopaminergic activity, potentially reducing side effects associated with traditional antipsychotics. MIN-117 targets multiple serotonin receptor subtypes and the serotonin transporter, with the aim of providing antidepressant benefit while minimizing common adverse events linked to selective serotonin reuptake inhibitors.

Headquartered in Cambridge, Massachusetts, Minerva Neurosciences operates research facilities in the United States and collaborates with academic partners and contract research organizations worldwide to advance its pipeline through clinical development. The company was founded in 2013 and has since progressed multiple candidates through Phase 1 and Phase 2 trials. Under the leadership of President and Chief Executive Officer Vipin K. Garg, Minerva continues to explore strategic partnerships and funding opportunities to support late‐stage clinical trials and, ultimately, regulatory submissions.

Key Stats

• Today's Range: $4.60 to $4.89
• 50-Day Range: $3.92 to $5.55
• 52-Week Range: $1.93 to $12.46
• Volume: 31,386 shs
• Average Volume: 217,650 shs
• Market Capitalization: $219.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.33
• Consensus Rating: Reduce

Minerva Neurosciences Stock Analysis - MarketRank™

Minerva Neurosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 607th out of 917 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Reduce

Consensus Rating

Minerva Neurosciences has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 2 sell ratings.

Upside Potential

Minerva Neurosciences has a consensus price target of $10.33, representing about 122.7% upside from its current price of $4.64.

Amount of Analyst Coverage

Minerva Neurosciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.73) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Minerva Neurosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Minerva Neurosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.74% of the float of Minerva Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Minerva Neurosciences has a short interest ratio ("days to cover") of 11.76, which indicates bearish sentiment.

Change versus previous month

Short interest in Minerva Neurosciences has recently decreased by 28.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Minerva Neurosciences does not currently pay a dividend.

Dividend Growth

Minerva Neurosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.93

News Sentiment

Minerva Neurosciences has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Minerva Neurosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Minerva Neurosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of Minerva Neurosciences is held by insiders.

Percentage Held by Institutions

34.56% of the stock of Minerva Neurosciences is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 8/31/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/09/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NERV
• CIK: 1598646
• Web: www.minervaneurosciences.com
• Phone: (617) 600-7373
• Fax: N/A
• Employees: 9
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Minerva Neurosciences: $10.33
• High Price Target: $14.00
• Low Price Target: $7.00
• Potential Upside/Downside: +124.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($28.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$293.42 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -31.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.15
• Quick Ratio: 20.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.25) per share
• Price / Book: -1.42

Miscellaneous

• Outstanding Shares: 47,748,000
• Free Float: 46,936,000
• Market Cap: $219.64 million
• Optionable: Not Optionable
• Beta: -0.10